Mexican Department of Public Health to Launch Screening for Human Papillomavirus (HPV), Cause of Cervical Cancer Nov 19, 2008
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies ... Investor Relations Dr. Solveigh Mahler Director Investor Relations QIAGEN N.V. +49-2103-29-11710 e-mail: Albert F. Fleury Director Corporate Finance and Investor Relations North America QIAGEN Gaithersburg, Inc. +1-301-944-7028 e-mail: Media Relations Dr. Thomas Theuringer Associate Director Public Relations QIAGEN GmbH +49-2103-29-11826 email: Myriam Maldonado Tapia - Gricorp Ketchum... (PR Newswire)
QIAGEN to Present At the 2008 UBS Global Life Sciences Conference Sep 18, 2008
VENLO, The Netherlands, Sept. 18, 2008 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NasdaqGS: - ) (Frankfurt: - ) today announced that it will present at the 2008 UBS Global Life Sciences Conference at 12:00 p.m. ET on Monday, September 22, 2008 ... QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies ... The QIAGEN N.V. logo is available at. (Primezone Releases)
QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues Feb 14, 2008
" About QIAGEN: QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein... (PR Newswire)
QIAGEN Wins Judgment Against Third Wave Jan 12, 2008
Jan. 11, 2008 (PRIME NEWSWIRE) -- QIAGEN Gaithersburg Inc. (formerly Digene Corporation), a wholly owned subsidiary of QIAGEN N.V. (NasdaqGS: - ) (Frankfurt: - ) today announced that it was granted summary judgment on the antitrust counterclaims asserted against it in QIAGEN's patent infringement suit against Third Wave Technologies, Inc. ... QIAGEN N.V., a Netherlands holding company, is the leading provider of innovative sample and assay technologies and products ... The QIAGEN N.V. logo is... (Primezone Releases)
QIAGEN to Present At the JPMorgan 26th Annual Healthcare Conference Dec 12, 2007
VENLO, The Netherlands, Dec. 12, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (NasdaqGS: - ) (Frankfurt: - ) today announced that it will present at the JPMorgan 26th Annual Healthcare Conference at 10:30 a.m. PT on Tuesday, January 8, 2008 ... QIAGEN N.V., a Netherlands holding company, is the leading provider of innovative sample and assay technologies and products ... The QIAGEN N.V. logo is available at. (Primezone Releases)
Study Finds New Version of QIAGEN's HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer by More than Half When Combined With Appropriate Treatment Nov 8, 2007
FastHPV -- a molecular test for cancer-causing types of HPV (human papillomavirus) -- is under development by QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) in partnership with PATH. The test -- on track to be submitted for its first regulatory approvals in countries like China and India in 2008 -- is specially designed to allow women in areas with scarce healthcare resources to benefit from the advanced technology of HPV testing ... About QIAGEN ) QIAGEN N.V., a Netherlands holding... (PR Newswire)
HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes Sep 18, 2007
5 CELERA GENOMICS GROUP-APPLER CRA 498126654 QIAGEN N.V. QGEN 368543571. 3 Affymetrix Inc. AFFX 252887591. (PR Newswire)
QIAGEN Announces Completion of Digene Acquisition Jul 31, 2007
VENLO, The Netherlands, July 30 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: ; Frankfurt, Prime Standard: QIA) announced today the successful completion of its acquisition of Digene Corporation (Nasdaq: DIGE) ... About QIAGEN QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. (PR Newswire)
Claim Construction Decision Issued in Digene's Patent Litigation With Third Wave Technologies Jul 25, 2007
Additional Information: QIAGEN N.V. has filed a Registration Statement on Form F-4, as amended, and a Schedule TO, as amended, and Digene has filed a Solicitation/Recommendation Statement on Schedule 14D-9, as amended, with the Securities and Exchange Commission in connection with QIAGEN's tender offer for Digene shares. QIAGEN and Digene commenced an exchange offer and mailed a Prospectus, which is part of the Registration Statement on Form F-4, the Solicitation/Recommendation Statement on... (PR Newswire)
Standard & Poor's Announces Changes to U.S. Indices Jul 24, 2007
Digene is being acquired by Qiagen N.V. in an exchange offer. -- PharMerica Corp. (NYSE: ) will replace Pope t Inc. (NYSE: ) in the SlCap 600 after the close of trading on Tuesday, July 31. (PR Newswire)
QIAGEN Exchange Offer for Digene Corporation Expired With Significant Over 90% of Shares Tendered Jul 23, 2007
VENLO, The Netherlands, July 23 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: ; Frankfurt, Prime Standard: QIA) today announced that its offer to exchange cash and stock for all outstanding shares of Digene Corporation (Nasdaq: ) expired as scheduled at 11:59 p.m., New York City time, on Friday, July 20, 2007 ... About QIAGEN QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. (PR Newswire)
QIAGEN and Digene Announce Expiration of Hart-Scott-Rodino Waiting Period Jul 17, 2007
VENLO, Netherlands and GAITHERSBURG, Md, July 17 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: ; Frankfurt, Prime Standard: QIA) and Digene Corp. (Nasdaq: ) announced that the antitrust waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired at 11:59 pm EDT on July 16, with respect to the previously announced merger of the two companies ... About QIAGEN QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay... (PR Newswire)
QIAGEN and Digene Announce Merger Creating Market and Technology Leader In Molecular Diagnostics Jun 4, 2007
June 3 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: ; Frankfurt, Prime Standard: QIA) and Digene Corp. (Nasdaq: ) announced today a definitive agreement to combine the two companies to create market- and technology-leadership in molecular diagnostics ... Conference Call Dial-in: +1-888-562-3356 Domestic +1-973-582-2700 International Passcode: 8863042 Replay Dial-in: +1-877-519-4471 Domestic +1-973-341-3080 International Passcode: 8863042 Webcast Access: or About QIAGEN QIAGEN N.V., a... (PR Newswire)
Digene sold to Dutch biotech Jun 4, 2007
Under the agreement, Netherlands-based Qiagen N.V. would pay $61. 25 for shares - up to $880 million - on a first-come, first-served basis. (Sunspot.net -- Business)
QIAGEN Launches First QIAplex Products for Highly Multiplexed, PCR-Based Assays Jun 1, 2007
QIAGEN N.V., a Netherlands holding company, is the leading provider of innovative sample and assay technologies and products ... The Qiagen N.V. logo is available at. (Primezone Releases)
QIAGEN and Biomatrica Announce Strategic Partnership Targeting Biological Sample Storage and Management Systems May 31, 2007
VENLO, The Netherlands, May 31, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (NasdaqGS: - ) (Frankfurt: - ), the worldwide leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics today announced that it has entered into a license and marketing agreement with Biomatrica, Inc. providing for the distribution of Biomatrica's room temperature DNA storage technology ... QIAGEN N.V., a Netherlands holding company, is the leading provider of... (Primezone Releases)
QIAGEN and Epigenomics Expand Successful Partnership May 29, 2007
BERLIN and VENLO, The Netherlands, May 29, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (NasdaqGS: - ) (Frankfurt: - ) (Prime Standard:QIA) and Epigenomics AG (Frankfurt: - ) (Prime Standard:ECX) today announced that the companies further expanded their existing strategic partnership by a new license agreement ... QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products ... QIAGEN N.V. IR QIAGEN N.V. +49 2103 29 11710 Fax. (Primezone Releases)
Ad Hoc: Epigenomics AG Expands Partnership With QIAGEN N.V. May 29, 2007
BERLIN and SEATTLE, May 29, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt: - ) today announced that it further expanded the existing strategic partnership with QIAGEN N.V. (NasdaqGS: - ) (Frankfurt: - ) by a new license agreement. ADVERTISEMENT. (Primezone Releases)
QIAGEN Signs Agreement for the Acquisition of eGene Apr 13, 2007
Strategic Transaction adds Capillary Sample Separation Technology VENLO, The Netherlands, April 12 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: ; Frankfurt, Prime Standard: QIA), the world's leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics, today announced, that its subsidiary QIAGEN North American Holdings, Inc. has signed a definitive merger agreement with eGene, Inc. (Nasdaq OTC/BB: EGEI) pursuant to which eGene would... (PR Newswire)
QIAGEN's Molecular Assays Detect Recently Discovered Chlamydia Trachomatis Strain Feb 28, 2007
QIAGEN N.V., a Netherlands holding company, is the leading provider of innovative sample and assay technologies and products. The products are considered standards in areas such as pre-analytical sample preparation and molecular diagnostics solutions. (Primezone Releases)
QIAGEN Unveils Revolutionary Sample Processing Platform Jan 29, 2007
The QIAcube Creates New Dimension of Utility for any User Conducting Molecular Biology VENLO, The Netherlands, January 29 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: , Frankfurt, Prime Standard: QIA), the worldwide leading provider of sample and assay technologies for life sciences, applied testing and molecular diagnostics, today announced the launch of the QIAcube - a compact platform incorporating novel and proprietary technologies that allows users to fully automate the processing of... (PR Newswire)
Sequenom and QIAGEN Enter Into Collaboration Targeting Prenatal Diagnostics Jan 8, 2007
SAN DIEGO and VENLO, Netherlands, Jan. 8 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: ) and QIAGEN GmbH, a wholly-owned subsidiary of QIAGEN N.V. (Nasdaq: ; Frankfurt, Prime Standard: QIA), today announced that they have entered into a strategic collaboration to jointly develop a gold-standard preanalytical solution for small molecule (fetal) DNA enrichment for prenatal diagnostics ... D. commented, "Non-invasive molecular diagnostics modalities will play an increasingly important role in... (PR Newswire)
QIAGEN and Pathway Diagnostics Sign Agreement to Address Biomarker Development Needs in Pharma Jan 8, 2007
Unique Offering Will Enhance Clinical Development and Validation of Biomarkers in Global Rrams and Clinical Trials VENLO, The Netherlands, January 8 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: , Frankfurt, Prime Standard: QIA), a leading provider of molecular diagnostics products and the world's premier supplier of solutions for preanalytical sample preparation, and Pathway Diagnostics Corporation (Malibu, CA), a pioneer in biomarker development and testing services for the pharmaceutical... (PR Newswire)
